Where are we now with the treatment of multiple myeloma?

The current standard-of-care therapy for patients with multiple myeloma is autologous stem-cell transplantation; however, whether this approach should be enhanced or displaced by triplet combination therapy is the subject of ongoing debate. We discuss the latest trial that has attempted to address t...

Full description

Saved in:
Bibliographic Details
Published inNature reviews. Clinical oncology Vol. 14; no. 8; pp. 461 - 462
Main Authors Morgan, Gareth J., Rasche, Leo
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.08.2017
Subjects
692/699/67/1059/99
692/699/67/1990/804
692/700/565/1436/1437
692/700/565/545/576
Medicine
Medicine & Public Health
news-and-views
Oncology
Online AccessGet full text

Cover

More Information
Summary:The current standard-of-care therapy for patients with multiple myeloma is autologous stem-cell transplantation; however, whether this approach should be enhanced or displaced by triplet combination therapy is the subject of ongoing debate. We discuss the latest trial that has attempted to address this question and the impact of transplantation and triplet therapy assessment and surrogate end points in future trial design.
ISSN:1759-4774
1759-4782
DOI:10.1038/nrclinonc.2017.82